Clinical trial
A Study to Evaluate Avastin in Patients Treated in a Previous…
NCT00096967 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096967 |
|---|---|
| Title | A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study |
| Official title | An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Colorectal Cancer, Metastases |
| Intervention type | Drug |
| Interventions | Avastin (bevacizumab) |
| Enrollment | 100 |
| Start date | Oct 1, 2002 |
| Completion | Jul 1, 2004 |
| First posted | Nov 18, 2004 |
| Last update posted | Mar 26, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: